Cargando…
Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
We herein investigated the detection frequency and clinical relevance of circulating tumor cells (CTCs) in chemotherapy-naïve stage IIIB/IV non-small cell lung cancer (NSCLC), by using the CellSearch and real-time CEACAM5mRNA assays. Blood samples from 43 patients were obtained at different time poi...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831933/ https://www.ncbi.nlm.nih.gov/pubmed/33477700 http://dx.doi.org/10.3390/ijms22020925 |
_version_ | 1783641725190799360 |
---|---|
author | Papadaki, Maria A. Messaritakis, Ippokratis Fiste, Oraianthi Souglakos, John Politaki, Eleni Kotsakis, Athanasios Georgoulias, Vassilis Mavroudis, Dimitrios Agelaki, Sofia |
author_facet | Papadaki, Maria A. Messaritakis, Ippokratis Fiste, Oraianthi Souglakos, John Politaki, Eleni Kotsakis, Athanasios Georgoulias, Vassilis Mavroudis, Dimitrios Agelaki, Sofia |
author_sort | Papadaki, Maria A. |
collection | PubMed |
description | We herein investigated the detection frequency and clinical relevance of circulating tumor cells (CTCs) in chemotherapy-naïve stage IIIB/IV non-small cell lung cancer (NSCLC), by using the CellSearch and real-time CEACAM5mRNA assays. Blood samples from 43 patients were obtained at different time points during first-line chemotherapy. CellSearch revealed the detection of ≥1 CTCs in 41.9%, 40.9%, and 16.7% of patients at baseline, post-1st, and post-2nd treatment cycle, respectively, and of ≥5 CTCs in 11.6%, 9.1%, and 5.6%, respectively. CEACAM5mRNA+ CTCs were detected in 29.3% and 16% of patients pre- and post-treatment, respectively. The positivity concordance between the two assays was 2.2%. CTC-detection by CellSearch (≥5 CTCs: p = 0.004), CEACAM5mRNA (p = 0.010), or by any assay (p = 0.000) was associated with disease progression. Reduced survival was demonstrated for patients harboring ≥5 CTCs (progression-free survival; PFS: p = 0.000; overall survival; OS: p = 0.009), CEACAM5mRNA+ CTCs (PFS: p = 0.043; OS: p = 0.039), and CTCs by any assay (PFS: p = 0.005; OS: p = 0.006, respectively). CTC-detection by any assay independently predicted for increased risk of relapse (hazard ratio; HR: 3.496; p = 0.001) and death (HR: 2.866; p = 0.008). CellSearch-positivity either pre-, post-1st, or post-2nd cycle, was predictive for shorter PFS (p = 0.036) compared to negativity in all time points. Persistent CEACAM5mRNA-positivity pre- and post-treatment was associated with reduced PFS (p = 0.036) and OS (p = 0.026). In conclusion, CTC detection and monitoring using the CellSearch and CEACAM5mRNA assays provides valuable and complementary clinical information for chemo-naïve advanced or metastatic NSCLC. |
format | Online Article Text |
id | pubmed-7831933 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-78319332021-01-26 Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Papadaki, Maria A. Messaritakis, Ippokratis Fiste, Oraianthi Souglakos, John Politaki, Eleni Kotsakis, Athanasios Georgoulias, Vassilis Mavroudis, Dimitrios Agelaki, Sofia Int J Mol Sci Article We herein investigated the detection frequency and clinical relevance of circulating tumor cells (CTCs) in chemotherapy-naïve stage IIIB/IV non-small cell lung cancer (NSCLC), by using the CellSearch and real-time CEACAM5mRNA assays. Blood samples from 43 patients were obtained at different time points during first-line chemotherapy. CellSearch revealed the detection of ≥1 CTCs in 41.9%, 40.9%, and 16.7% of patients at baseline, post-1st, and post-2nd treatment cycle, respectively, and of ≥5 CTCs in 11.6%, 9.1%, and 5.6%, respectively. CEACAM5mRNA+ CTCs were detected in 29.3% and 16% of patients pre- and post-treatment, respectively. The positivity concordance between the two assays was 2.2%. CTC-detection by CellSearch (≥5 CTCs: p = 0.004), CEACAM5mRNA (p = 0.010), or by any assay (p = 0.000) was associated with disease progression. Reduced survival was demonstrated for patients harboring ≥5 CTCs (progression-free survival; PFS: p = 0.000; overall survival; OS: p = 0.009), CEACAM5mRNA+ CTCs (PFS: p = 0.043; OS: p = 0.039), and CTCs by any assay (PFS: p = 0.005; OS: p = 0.006, respectively). CTC-detection by any assay independently predicted for increased risk of relapse (hazard ratio; HR: 3.496; p = 0.001) and death (HR: 2.866; p = 0.008). CellSearch-positivity either pre-, post-1st, or post-2nd cycle, was predictive for shorter PFS (p = 0.036) compared to negativity in all time points. Persistent CEACAM5mRNA-positivity pre- and post-treatment was associated with reduced PFS (p = 0.036) and OS (p = 0.026). In conclusion, CTC detection and monitoring using the CellSearch and CEACAM5mRNA assays provides valuable and complementary clinical information for chemo-naïve advanced or metastatic NSCLC. MDPI 2021-01-18 /pmc/articles/PMC7831933/ /pubmed/33477700 http://dx.doi.org/10.3390/ijms22020925 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Papadaki, Maria A. Messaritakis, Ippokratis Fiste, Oraianthi Souglakos, John Politaki, Eleni Kotsakis, Athanasios Georgoulias, Vassilis Mavroudis, Dimitrios Agelaki, Sofia Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) |
title | Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) |
title_full | Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) |
title_fullStr | Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) |
title_full_unstemmed | Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) |
title_short | Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) |
title_sort | assessment of the efficacy and clinical utility of different circulating tumor cell (ctc) detection assays in patients with chemotherapy-naïve advanced or metastatic non-small cell lung cancer (nsclc) |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831933/ https://www.ncbi.nlm.nih.gov/pubmed/33477700 http://dx.doi.org/10.3390/ijms22020925 |
work_keys_str_mv | AT papadakimariaa assessmentoftheefficacyandclinicalutilityofdifferentcirculatingtumorcellctcdetectionassaysinpatientswithchemotherapynaiveadvancedormetastaticnonsmallcelllungcancernsclc AT messaritakisippokratis assessmentoftheefficacyandclinicalutilityofdifferentcirculatingtumorcellctcdetectionassaysinpatientswithchemotherapynaiveadvancedormetastaticnonsmallcelllungcancernsclc AT fisteoraianthi assessmentoftheefficacyandclinicalutilityofdifferentcirculatingtumorcellctcdetectionassaysinpatientswithchemotherapynaiveadvancedormetastaticnonsmallcelllungcancernsclc AT souglakosjohn assessmentoftheefficacyandclinicalutilityofdifferentcirculatingtumorcellctcdetectionassaysinpatientswithchemotherapynaiveadvancedormetastaticnonsmallcelllungcancernsclc AT politakieleni assessmentoftheefficacyandclinicalutilityofdifferentcirculatingtumorcellctcdetectionassaysinpatientswithchemotherapynaiveadvancedormetastaticnonsmallcelllungcancernsclc AT kotsakisathanasios assessmentoftheefficacyandclinicalutilityofdifferentcirculatingtumorcellctcdetectionassaysinpatientswithchemotherapynaiveadvancedormetastaticnonsmallcelllungcancernsclc AT georgouliasvassilis assessmentoftheefficacyandclinicalutilityofdifferentcirculatingtumorcellctcdetectionassaysinpatientswithchemotherapynaiveadvancedormetastaticnonsmallcelllungcancernsclc AT mavroudisdimitrios assessmentoftheefficacyandclinicalutilityofdifferentcirculatingtumorcellctcdetectionassaysinpatientswithchemotherapynaiveadvancedormetastaticnonsmallcelllungcancernsclc AT agelakisofia assessmentoftheefficacyandclinicalutilityofdifferentcirculatingtumorcellctcdetectionassaysinpatientswithchemotherapynaiveadvancedormetastaticnonsmallcelllungcancernsclc |